AU2007261568B2 - Substituted 8-[6-amino-3-pyridyl]xanthines - Google Patents

Substituted 8-[6-amino-3-pyridyl]xanthines Download PDF

Info

Publication number
AU2007261568B2
AU2007261568B2 AU2007261568A AU2007261568A AU2007261568B2 AU 2007261568 B2 AU2007261568 B2 AU 2007261568B2 AU 2007261568 A AU2007261568 A AU 2007261568A AU 2007261568 A AU2007261568 A AU 2007261568A AU 2007261568 B2 AU2007261568 B2 AU 2007261568B2
Authority
AU
Australia
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
meoh
gradient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007261568A
Other languages
English (en)
Other versions
AU2007261568A1 (en
Inventor
Jayson M. Rieger
Robert D. Thompson
Guoquan Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Sales LLC
Original Assignee
Allergan Sales LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Sales LLC filed Critical Allergan Sales LLC
Priority claimed from PCT/US2007/013849 external-priority patent/WO2007149277A2/en
Publication of AU2007261568A1 publication Critical patent/AU2007261568A1/en
Assigned to TROVIS PHARMACEUTICALS LLC reassignment TROVIS PHARMACEUTICALS LLC Alteration of Name(s) of Applicant(s) under S113 Assignors: PGX HEALTH, LLC
Assigned to DOGWOOD PHARMACEUTICALS, INC. reassignment DOGWOOD PHARMACEUTICALS, INC. Request for Assignment Assignors: TROVIS PHARMACEUTICALS LLC
Application granted granted Critical
Publication of AU2007261568B2 publication Critical patent/AU2007261568B2/en
Assigned to ALLERGAN SALES, LLC reassignment ALLERGAN SALES, LLC Request for Assignment Assignors: DOGWOOD PHARMACEUTICALS, INC.
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2007261568A 2006-06-16 2007-06-13 Substituted 8-[6-amino-3-pyridyl]xanthines Ceased AU2007261568B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US80503006P 2006-06-16 2006-06-16
US60/805,030 2006-06-16
US80556406P 2006-06-22 2006-06-22
US60/805,564 2006-06-22
US11/811,823 2007-06-12
US11/811,823 US7884100B2 (en) 2006-06-16 2007-06-12 Substituted 8-[6-amino-3-pyridyl]xanthines
PCT/US2007/013849 WO2007149277A2 (en) 2006-06-16 2007-06-13 Substituted 8-[6-amino-3-pyridyl]xanthines

Publications (2)

Publication Number Publication Date
AU2007261568A1 AU2007261568A1 (en) 2007-12-27
AU2007261568B2 true AU2007261568B2 (en) 2013-05-16

Family

ID=56290980

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007261568A Ceased AU2007261568B2 (en) 2006-06-16 2007-06-13 Substituted 8-[6-amino-3-pyridyl]xanthines

Country Status (18)

Country Link
US (2) US7884100B2 (enExample)
EP (1) EP2029143B1 (enExample)
JP (1) JP5417558B2 (enExample)
KR (1) KR101413404B1 (enExample)
CN (1) CN103145712A (enExample)
AU (1) AU2007261568B2 (enExample)
BR (1) BRPI0712001B8 (enExample)
CA (1) CA2655598C (enExample)
DK (1) DK2029143T3 (enExample)
EA (1) EA016791B1 (enExample)
ES (1) ES2548437T3 (enExample)
HU (1) HUE026457T2 (enExample)
IL (1) IL195916A (enExample)
MX (1) MX2008015954A (enExample)
MY (1) MY152178A (enExample)
NZ (1) NZ597222A (enExample)
PL (1) PL2029143T3 (enExample)
PT (1) PT2029143E (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7317017B2 (en) * 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
EP1658291B1 (en) * 2003-08-25 2013-10-02 Dogwood Pharmaceuticals, Inc. Substituted 8-heteroaryl xanthines
WO2006091897A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Derivatives of 8-substituted xanthines
US7598379B2 (en) * 2005-02-25 2009-10-06 Pgx Health, Llc Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
WO2006091898A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Pyrazolyl substituted xanthines
US7884100B2 (en) 2006-06-16 2011-02-08 Pgxhealth, Llc Substituted 8-[6-amino-3-pyridyl]xanthines
US7875608B2 (en) * 2007-12-17 2011-01-25 Thompson Robert D Substituted 8-[6-amino-3pyridyl]xanthines
CA3218963A1 (en) 2021-05-18 2022-11-24 Robert Thompson Cyclic amide-containing pyridyl xanthines as a2b antagonists

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050065341A1 (en) * 2003-08-25 2005-03-24 Guoquan Wang Substituted 8-heteroaryl xanthines

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
US6060481A (en) 1998-05-28 2000-05-09 The Penn State Research Foundation Method for improving insulin sensitivity using an adenosine receptor antagonist
GB9817623D0 (en) 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
US6894021B2 (en) * 2000-02-17 2005-05-17 Cv Therapeutics, Inc. Method for identifying and using A2B adenosine receptor antagonists to mediate mammalian cell proliferation
AU2002359365B2 (en) 2001-11-09 2008-07-10 Gilead Sciences, Inc. A2B adenosine receptor antagonists
US7317017B2 (en) * 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US6977300B2 (en) 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7304070B2 (en) 2001-11-09 2007-12-04 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
MXPA03008967A (es) 2002-02-01 2004-02-12 King Pharmaceuticals Res & Dev Antagonistas receptores de 8-heteroarilo xantina adenosina a-2b.
US7034070B2 (en) * 2002-09-27 2006-04-25 Vincent Chuang Arylalkyl aminofunctional silanes for epoxy laminates
US7148229B2 (en) 2003-02-19 2006-12-12 Hoffman-La Roche Inc. Sulfonamide substituted xanthine derivatives
PL1789053T3 (pl) 2004-09-01 2012-12-31 Gilead Sciences Inc Sposób gojenia się rany wykorzystujący antagonistów receptora adenozynowego A2B
US20060053029A1 (en) 2004-09-03 2006-03-09 Butler Keith R Methods and systems for providing an enterprise supply management portal
EP2311462A1 (en) 2004-10-15 2011-04-20 Cv Therapeutics, Inc. Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists
WO2006091898A2 (en) 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Pyrazolyl substituted xanthines
WO2006091896A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Pyridyl substituted xanthines
US7598379B2 (en) * 2005-02-25 2009-10-06 Pgx Health, Llc Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
WO2006091897A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Derivatives of 8-substituted xanthines
CA2612344A1 (en) 2005-06-16 2006-12-28 Cv Therapeutics, Inc. Prodrugs of a2b adenosine receptor antagonists
CA2646333C (en) * 2006-03-17 2014-06-17 Cv Therapeutics, Inc. Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists
WO2007149115A1 (en) * 2006-06-15 2007-12-27 Targeted Genetics Corporation Methods for treating target joints in inflammatory arthritis using aav vectors encoding a tnf antagonist
US7884100B2 (en) 2006-06-16 2011-02-08 Pgxhealth, Llc Substituted 8-[6-amino-3-pyridyl]xanthines
US7767685B2 (en) 2006-06-29 2010-08-03 King Pharmaceuticals Research And Development, Inc. Adenosine A2B receptor antagonists
US7875608B2 (en) * 2007-12-17 2011-01-25 Thompson Robert D Substituted 8-[6-amino-3pyridyl]xanthines
JP5460690B2 (ja) 2008-03-26 2014-04-02 アドヴィナス・セラピューティックス・リミテッド アデノシンレセプターアンタゴニストとしてのヘテロ環化合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050065341A1 (en) * 2003-08-25 2005-03-24 Guoquan Wang Substituted 8-heteroaryl xanthines

Also Published As

Publication number Publication date
US20080004292A1 (en) 2008-01-03
IL195916A0 (en) 2009-09-01
IL195916A (en) 2015-06-30
DK2029143T3 (en) 2015-09-21
EA200900010A1 (ru) 2009-10-30
HUE026457T2 (en) 2016-05-30
CA2655598C (en) 2014-10-28
NZ597222A (en) 2013-06-28
CN103145712A (zh) 2013-06-12
CA2655598A1 (en) 2007-12-27
EA016791B1 (ru) 2012-07-30
MX2008015954A (es) 2009-03-06
BRPI0712001B8 (pt) 2021-05-25
EP2029143B1 (en) 2015-07-08
JP5417558B2 (ja) 2014-02-19
US7884100B2 (en) 2011-02-08
JP2010500284A (ja) 2010-01-07
PL2029143T3 (pl) 2015-12-31
AU2007261568A1 (en) 2007-12-27
BRPI0712001A2 (pt) 2012-01-10
BRPI0712001B1 (pt) 2020-04-07
PT2029143E (pt) 2015-10-20
US8258142B2 (en) 2012-09-04
ES2548437T3 (es) 2015-10-16
KR101413404B1 (ko) 2014-06-27
MY152178A (en) 2014-08-15
US20110082139A1 (en) 2011-04-07
KR20090029268A (ko) 2009-03-20
EP2029143A2 (en) 2009-03-04
EP2029143A4 (en) 2009-07-15

Similar Documents

Publication Publication Date Title
EP2295434B1 (en) Substituted 8-heteroaryl xanthines
US8153628B2 (en) Pyrazolyl substituted xanthines
WO2006091897A2 (en) Derivatives of 8-substituted xanthines
WO2000073307A2 (en) Substituted 8-phenylxanthines useful as antagonists of a2b adenosine receptors
US7601723B2 (en) Pyridyl substituted xanthines
US8258142B2 (en) Substituted 8-[6-amino-3-pyridyl]xanthines
US7875608B2 (en) Substituted 8-[6-amino-3pyridyl]xanthines
US8349848B2 (en) Pyrrolo[3,2-D]pyrimidines that are selective antagonists of A2B adenosine receptors
WO2011005871A1 (en) Substituted 8-[6-carbonylamine-3-pyridyl]xanthines as adenosine a2b antagonists
WO2007149277A2 (en) Substituted 8-[6-amino-3-pyridyl]xanthines
WO2006091936A2 (en) Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
HK1131569A (en) Substituted 8-[6-amino-3-pyridyl]xanthines

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE PRIORITY DETAILS UNDER INID (31) 60/805,864; INID (32) 22.06.06; INID (33) US TO INID (31) 60/805,564; INID (32) 22.06.06; INID (33) US

PC1 Assignment before grant (sect. 113)

Owner name: DOGWOOD PHARMACEUTICALS, INC.

Free format text: FORMER APPLICANT(S): TROVIS PHARMACEUTICALS LLC

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: ALLERGAN SALES, LLC

Free format text: FORMER OWNER(S): DOGWOOD PHARMACEUTICALS, INC.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired